BIDOLI PAOLO

Ruolo: 
Professore associato
Settore scientifico disciplinare: 
ONCOLOGIA MEDICA (MED/06)

Pubblicazioni

  • Massironi, S., Pilla, L., Elvevi, A., Longarini, R., Rossi, R., Bidoli, P., et al. (2020). New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. CELLS, 9(3). Dettaglio
  • Sharma, G., Cortinovis, D., Agustoni, F., Arosio, G., Villa, M., Cordani, N., et al. (2019). A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. JOURNAL OF THORACIC ONCOLOGY, 14(11), e257-e259. Dettaglio
  • Vernieri, C., Galli, F., Ferrari, L., Marchetti, P., Lonardi, S., Maiello, E., et al. (2019). Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. THE ONCOLOGIST, 24(3), 385-393. Dettaglio
  • Cavaletti, G., Cornblath, D., Merkies, I., Postma, T., Rossi, E., Alberti, P., et al. (2019). Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 24(1), 111-119. Dettaglio
  • Esposito Abate, R., Pasquale, R., Sacco, A., Piccirillo, M., Morabito, A., Bidoli, P., et al. (2019). Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib. CANCERS, 11(10). Dettaglio